Drugs / INP12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06589401 | Sep 2022 → Oct 2025 overdue | neoplasm | InnoUp Farma S.L. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INP12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589401 ↗ |
| Known as | paclitaxel | “Phase I trial evaluating the safety, tolerability, and pharmacokinetic profile of INP12, a nanoparticles-based oral paclitaxel, in patients with advanced solid tumors” NCT06589401 ↗ |
| Route | Oral | “INP12 administered orally once a week” NCT06589401 ↗ |